Celiac drug development just took a serious hit.
Takeda’s latest pipeline no longer lists TAK-101 or TAK-062.
That matters.
Small biotech companies can discover brilliant science.
But major pharmaceutical companies bring the money, regulatory experience and massive clinical trials required to turn that science into an approved treatment.
Takeda brought all three.
Now two celiac programs are gone from its pipeline.
That does not mean celiac science is dead.
It means the path from promising science to an actual treatment just became harder.
We cannot keep celebrating every new Phase 1 trial without acknowledging the treatments that disappear.
The celiac community deserves the whole story—not just the hopeful parts.
Keep Reading: The Celiac Treatment Pipeline
Drug-development setbacks do not mean the science is dead. They show why the complete history matters.
- TEV-408 for Celiac Disease: Promising, But I Have Questions
- September Celiac News: ZED1227, Gluten Is a Joke & More
- What the Nexvax2 Clinical Trial Taught Me About Gluten Reactions
- When the Nexvax2 Trial Was Shut Down
Next in this series: Why we still cannot easily determine whether the gluten-free diet is working.
Leave a Reply